Sunday, 7 January 2018

MSF - HIV and AIDS in Africa

New research Doctors Without Borders has presented at the recent International Conference on AIDS and STIs in Africa (ICASA2017):

Outcomes of HIV infected persons receiving treatment for Kaposi’s Sarcoma in Conakry, Guinea (abstract): HIV+ people in Guinea—where 75 percent are not on treatment—are dying needlessly when access to care could help them live long, healthy lives. Unfortunately, because many aren’t on antiretroviral therapy to help slow the progression of HIV/AIDS, MSF is treating cases of AIDS-related opportunistic infections like Kaposi's Sarcoma at very late stages when the response rate to care is poor. Early diagnosis, increased access to treatment options (including chemotherapy), and access to new drugs could help improve the lives of HIV+ people in Guinea.

Preliminary results of evaluation of the use of GeneXpert HIV-1 Qual assay for decentralized early infant diagnosis (abstract): Diagnostics like GeneXpert are critical in the field, especially the settings in which MSF works because there aren’t often full laboratories in the region to help with diagnoses. This abstract shows that making diagnosis easier and quicker through a decentralized model means babies can be tested for HIV and put on treatment more quickly, reducing cases of morbidity and mortality.

Clinical and immunological HIV outcomes in a conflict setting in the Central African Republic (abstract): CAR has the highest mortality rate for people living with HIV of any country in the world. One of the main barriers to care in a conflict setting like CAR is stock-outs of antiretrovirals, which results in fewer people getting the medicines they need in the first place as well as interruptions for those already on treatment regimens. However, different models of care and program flexibility can help keep people on treatment in violence-affected and unstable regions.

Posted by Dr. Tim Sandle

No comments:

Post a Comment

Pharmaceutical Microbiology Resources

Special offers